Medical Supplies

Bayer’s Consumer Health Division Announces Changes to North America Leadership Team

Retrieved on: 
Tuesday, April 9, 2024
Other Communications, Other Health, Marketing, Communications, General Health, Other Natural Resources, Fitness & Nutrition, Agriculture, Natural Resources, Science, Vitamins, Supplements, Other Science, Health, Research, Medical Supplies, Growth, Philosophy, Business administration, BBDO, Diversity, University, Equity, Walmart, Bayer, Love, P&G, Aspirin, BBA, CMO, Tenneco, Multimedia, Loratadine, Advance Auto Parts, Avivi

Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.

Key Points: 
  • Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.
  • She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer.
  • View the full release here: https://www.businesswire.com/news/home/20240409885941/en/
    “I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi.
  • “I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi.

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

Collette Health Debuts Three Major Platform Enhancements at AONL 2024 Conference to Increase Patient Safety

Retrieved on: 
Tuesday, April 9, 2024
Technology, Medical Supplies, Health Technology, Telemedicine, Virtual Medicine, Software, Other Health, Hardware, Managed Care, General Health, Health, Hospital, Thoroughfare, Conference, Documentation, Risk, EMR, Patient, Observation, AI, System, Safety, Patient safety, Machine learning, Multimedia, ICU, Nursing

Collette Health , a leading provider of continuous virtual patient observation solutions, announced today at the 2024 American Organization for Nursing Leadership (AONL) Conference three new major platform enhancements to increase patient safety and allow care from anywhere.

Key Points: 
  • Collette Health , a leading provider of continuous virtual patient observation solutions, announced today at the 2024 American Organization for Nursing Leadership (AONL) Conference three new major platform enhancements to increase patient safety and allow care from anywhere.
  • “This is a major milestone for Collette Health, and we’re proud to unveil and introduce these new features at AONL in front of thousands of nursing leaders,” said Christine Gall, Chief Nursing Officer at Collette Health.
  • Collette Health uses a strategic and human-enabled application of AI and machine learning (ML) with its new “follow patient” feature.
  • Collette Health will be exhibiting and demonstrating its platform at the AONL Conference in New Orleans, April 9-10.

Orthobond Secures De Novo Classification Grant for First-in-Class Antibacterial Surface Treatment Applied to a Spinal Device

Retrieved on: 
Monday, April 8, 2024
Medical Supplies, Medical Devices, FDA, Health, Dental, Biotechnology, De novo, Textile, Patient, Corporation, Sterilization, Bacteria, Operating, Infection, Pain, Physician, Food, Sports medicine

Orthobond Corporation , a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced today that the U.S. Food and Drug Administration (FDA) granted its De Novo marketing request for the use of Ostaguard™, its proprietary antibacterial surface treatment, on a permanent medical device.

Key Points: 
  • Orthobond Corporation , a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced today that the U.S. Food and Drug Administration (FDA) granted its De Novo marketing request for the use of Ostaguard™, its proprietary antibacterial surface treatment, on a permanent medical device.
  • Numerous studies have shown between 70-100% of explanted hardware from failed joint implants have some level of contamination from different sources.
  • Orthobond pioneered a method to covalently-bond its antibacterial molecule to the surface of implants.
  • The proprietary surface technology is applied during the manufacturing process prior to packaging and sterilization.

Exact Sciences Schedules First Quarter 2024 Earnings Call

Retrieved on: 
Monday, April 8, 2024
General Health, Health, Oncology, Medical Supplies, Webcast

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024.

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024.
  • Following the release, company management will host a webcast and conference call at 5 p.m.
  • ET to discuss financial results and business progress.

FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose

Retrieved on: 
Monday, April 8, 2024
General Health, FDA, Health, Pharmaceutical, Medical Supplies, Hypoventilation, Hypersensitivity, Nalmefene, Pulmonary edema, Caregiver, Safety, Tachycardia, Risk, New Drug Application, Patient, Ventricular tachycardia, Naloxone, Health care, Buprenorphine, Mortality, NDA, MD, Methadone, Ventricular fibrillation, Hypotension, Oxygen, LAAM, Recurrence, Allergy, Purdue University, Hypertension, Fentanyl, Pharmaceutical industry

Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.

Key Points: 
  • Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
  • "Through this auto-injector FDA submission, our goal is to help expand the availability of nalmefene to the community alongside existing available options for healthcare professionals.
  • Priority review status means that FDA will expedite the review process to evaluate a drug that would significantly improve treatment of a serious condition.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.

Electromed, Inc. to Participate in the 2024 Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Retrieved on: 
Monday, April 8, 2024
General Health, Health, Medical Supplies, Medical Devices, Conference

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the 2024 Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 17-18, 2024.

Key Points: 
  • Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the 2024 Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 17-18, 2024.
  • Electromed’s management team will present at 10:30 a.m. Eastern Time on Thursday, April 18, 2024.
  • To view the live webcast, you can register for the conference for free, here .
  • An archived webcast of the event will be available shortly after the event on the Electromed website under Events & Presentations .

Thermo Fisher Scientific Launches New ENERGY STAR certified TSX Universal Series ULT Freezers to Deliver Tighter Temperature Control and Faster Recovery Times

Retrieved on: 
Monday, April 8, 2024
Other Health, Research, Pharmaceutical, Sustainability, Medical Devices, Environment, Health Technology, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, ACT, Temperature, Thermo Fisher Scientific, Laboratory, GMP, TSX, ULT, Multimedia, ISO, Medical device

Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.

Key Points: 
  • Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.
  • With enhancements to performance, user experience and energy efficiency, the Thermo Scientific™ TSX™ Universal Series ULT Freezers seamlessly adapt to scientists’ workflows across a variety of lab settings, marking a new era in performance, reliability, and sustainability.
  • With Universal V-Drive technology, tighter control, faster recovery times, universal voltage, and an expanded setpoint range, the TSX Universal Series seamlessly adapts to diverse workflows, from high-use academic labs to longer-term storage facilities.
  • Delivering both industry leading performance and energy efficiency, the TSX Universal Series allows labs to meet their sustainability goals without sacrificing performance.

Kenvue to Announce First Quarter 2024 Results on May 7, 2024

Retrieved on: 
Friday, April 5, 2024
Biotechnology, General Health, Other Health, Health, Medical Supplies, ID, Webcast, KVUE, Inc.

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024.
  • The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results.
  • The conference call can be accessed by dialing 888-672-2415 from the U.S. or +1 646-307-1952 from international locations.
  • A live webcast of the conference call will be available at investors.kenvue.com .

Stevanato Group appoints Ugo Gay as Chief Operations Officer

Retrieved on: 
Thursday, April 4, 2024
Medical Supplies, Medical Devices, Health, Other Health, Pharmaceutical, Biotechnology, Organization, DiaSorin, Growth, Stevanato Group, Information, Piombino Dese, Ugo, Investment, Multimedia, Development, Management

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
  • View the full release here: https://www.businesswire.com/news/home/20240404727049/en/
    Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire)
    The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain.
  • Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations.
  • “I am honored to help lead Stevanato Group's journey towards operational excellence, driving sustainable growth across our global footprint while fostering innovation," said Ugo Gay, Chief Operations Officer at Stevanato Group.